DE102005056103A1 - Agent, useful to treat diabetes, comprises 5-D-fructose-dehydrogenase and glucose isomerase - Google Patents
Agent, useful to treat diabetes, comprises 5-D-fructose-dehydrogenase and glucose isomerase Download PDFInfo
- Publication number
- DE102005056103A1 DE102005056103A1 DE102005056103A DE102005056103A DE102005056103A1 DE 102005056103 A1 DE102005056103 A1 DE 102005056103A1 DE 102005056103 A DE102005056103 A DE 102005056103A DE 102005056103 A DE102005056103 A DE 102005056103A DE 102005056103 A1 DE102005056103 A1 DE 102005056103A1
- Authority
- DE
- Germany
- Prior art keywords
- fructose
- glucose
- agent
- glucose isomerase
- dehydrogenase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108700040099 Xylose isomerases Proteins 0.000 title claims abstract description 23
- 239000003795 chemical substances by application Substances 0.000 title claims abstract description 17
- 206010012601 diabetes mellitus Diseases 0.000 title claims description 15
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 31
- 239000008103 glucose Substances 0.000 claims abstract description 31
- 235000013305 food Nutrition 0.000 claims abstract description 9
- 101710088194 Dehydrogenase Proteins 0.000 claims description 19
- 239000004480 active ingredient Substances 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 5
- 230000000694 effects Effects 0.000 abstract description 14
- 230000003178 anti-diabetic effect Effects 0.000 abstract 1
- 239000003472 antidiabetic agent Substances 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 14
- 229930091371 Fructose Natural products 0.000 description 12
- 239000005715 Fructose Substances 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- AWQIYVPBMVSGCL-PHDIDXHHSA-N 5-dehydro-D-fructose Chemical compound OCC(=O)[C@@H](O)[C@H](O)C(=O)CO AWQIYVPBMVSGCL-PHDIDXHHSA-N 0.000 description 8
- HDBDSFLMOWWRBQ-UHFFFAOYSA-N 5-fructonose Natural products OC1C(O)C2(O)COC1(O)CO2 HDBDSFLMOWWRBQ-UHFFFAOYSA-N 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 3
- 229940038472 dicalcium phosphate Drugs 0.000 description 3
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- 210000004913 chyme Anatomy 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 208000001921 latent autoimmune diabetes in adults Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000008953 bacterial degradation Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- -1 sucrose Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/52—Isomerases (5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
Abstract
Description
Gegenstand der Erfindung ist ein Mittel zur Anwendung bei Diabetes, welches den Glucosegehalt der Nahrung und sonstiger verzehrter Stoffe reduziert. Dabei werden unter dem Begriff „Diabetes" im Sinne dieser Patenanmeldung sämtliche Formen gestörten Blutzuckerstoffwechsels einschließlich aller Formen von Diabetes, wie z.B. Diabetes I einschließlich LADA-Diabetes (latent autoimmune diabetes in adults), Diabetes II und Schwangerschaftsdiabetes verstanden. Die Erfindung ist demnach auch für Personen geeignet, deren Blutzuckerstoffwechsel nur geringfügig gestört ist, so daß sie (noch) nicht als Diabetiker im medizinischen Sinne bezeichnet werden.object The invention is an agent for use in diabetes which reduces the glucose content of food and other consumed substances. In this case, the term "diabetes" in the sense of this patent application all Distorted forms Blood sugar metabolism including all forms of diabetes, such as. Including diabetes i LADA diabetes (latent autoimmune diabetes in adults), diabetes II and gestational diabetes understood. The invention is accordingly also for Suitable persons whose blood sugar metabolism is only slightly disturbed, so that you (yet) not to be referred to as a diabetic in the medical sense.
Unter glucosehaltig werden im Sinne dieser Patentanmeldung alle Stoffe und Nahrungsmittel verstanden, welche entweder Glucose in Reinform enthalten, oder aus denen im Verdauungstrakt Glucose freigesetzt werden kann, wie z.B. aus Saccharose. Aus dieser wird im Darm durch enzymatische Spaltung Glucose und Fructose zu gleichen Teilen freigesetzt.Under containing glucose for the purposes of this patent application all substances and understood foods which are either glucose in pure form contain or released from glucose in the digestive tract can be, such as from sucrose. This is going through in the intestine enzymatic cleavage of glucose and fructose released in equal parts.
Die bisherigen Therapien bei Blutzuckerstoffwechselstörungen beschränken sich im Wesentlichen darauf, den Insulingehalt im Blut zu erhöhen (durch das Zuführen von Insulin oder durch das Verstärken der Insulinausschüttung) bzw. die Insulinwirksamkeit zu verstärken. Ein anderer Weg besteht in der Verzögerung der Aufnahme von Kohlenhydraten (Resorptionsverzögerer) mit der Folge von abdominellen Beschwerden wegen des bakteriellen Abbaus der in die unteren Darmabschnitte gelangenden Kohlenhydrate.The Previous therapies for blood sugar metabolism disorders are limited essentially to increase the insulin content in the blood (through the feeding of insulin or by strengthening the insulin distribution) or to increase insulin activity. Another way is in the delay the absorption of carbohydrates (absorption retardants) with the consequence of abdominal Complaints of bacterial degradation in the lower intestinal sections getting carbohydrates.
Trotz aller bisher gefundenen Behandlungsmöglichkeiten von Diabetes besteht weiterhin ein Bedarf an Mitteln, die auf schonende Weise das Ansteigen des Blutzuckerspiegels in Folge der Zufuhr glucosehaltiger Nahrung und Stoffe verhindern oder verringern. Dies kann erfindungsgemäß durch die Kombination zweier Enzyme erreicht werden. Dabei handelt es sich um die Enzyme 5-D-Fructose-Dehydrogenase und Glucose-Isomerase.In spite of All previously found treatment options for diabetes there continues to be a need for resources that gently increase blood sugar levels as a result of the intake of glucose-containing food and prevent or reduce substances. This can according to the invention the combination of two enzymes can be achieved. It is the enzymes 5-D-fructose dehydrogenase and glucose isomerase.
Das Enzym 5-D-Fructose-Dehydrogenase bewirkt die Umwandlung von D-Fructose zu 5-Keto-D-Fructose. Das Enzym Glucose-Isomerase bewirkt die Umwandlung von Glucose in Fructose und umgekehrt. Hierbei stellt sich – je nach vorliegender Temperatur – ein Gleichgewicht mit etwa 50% Glucose und 50% Fructose ein.The Enzyme 5-D-fructose dehydrogenase causes the conversion of D-fructose to 5-keto-D-fructose. The enzyme glucose isomerase causes the conversion of glucose into Fructose and vice versa. Here, depending on the present temperature - a balance with about 50% glucose and 50% fructose.
Die erfindungsgemäße Wirkung der Enzymkombination sei am Beispiel der Stärke erläutert. Da aus Stärke während der Verdauung vor allem Glucose als Monosaccharid freigesetzt wird, wird diese von der Glucose-Isomerase in Fructose überführt, welche dann von der 5-D-Fructose-Dehydrogenase in die vom Körper nicht verwertbare 5-Keto-D-Fructose umgewandelt wird. Die 5-D-Fructose-Dehydrogenase verhindert so, dass sich das oben beschriebene Gleichgewicht einstellen kann. Daher wird die Glucose-Isomerase so lange Glucose in Fructose, welche ihrerseits von der 5-D-Fructose-Dehydrogenase in 5-Keto-D-Fructose dehydriert wird, umwandeln, bis keine Glucose mehr in der Nahrung bzw. dem Speisebrei vorhanden ist.The effect according to the invention the enzyme combination is explained using the example of the starch. Because of strength during the Digestion especially glucose is released as a monosaccharide, This is converted by the glucose isomerase in fructose, which then converted from 5-D-fructose dehydrogenase into 5-keto-D-fructose which is not usable by the body becomes. 5-D-fructose dehydrogenase prevents the balance described above from occurring can. Therefore, the glucose isomerase is glucose in fructose, which in turn is derived from 5-D-fructose dehydrogenase in 5-keto-D-fructose dehydrates, convert until there is no more glucose in the diet or the chyme is present.
Auch bei Saccharose läßt sich mit diesem Kombinationsmittel eine Glucosereduzierung erreichen. Die während der Verdauung aus der Saccharose freigesetzte Fructose wird, wie oben beschrieben, von der 5-D-Fructose-Dehydrogenase in 5-Keto-D-Fructose umgewandelt. Die Glucose-Isomerase wird daraufhin versuchen, das sich ergebende Ungleichgewicht auszugleichen, in dem sie Glucose zu Fructose umwandelt. Dieser Umwandlungsprozess wird wiederum so lange weitergehen, bis keine Glucose mehr im Speisebrei vorhanden ist. Es ist möglich, dass bis dahin ein Teil der für den Organismus leicht verwertbaren Glucose bereits resorbiert worden ist. Jedoch wird die Menge der insgesamt aus einer zuckerhaltigen Mahlzeit resorbierten Glucose mit Hilfe der hier vorgestellten Erfindung erheblich reduziert werden. Je nach dem wie hoch die Enzymaktivität pro Dosiseinheit und wie hoch der Glucosegehalt der jeweiligen Mahlzeit ist, lässt sich die Menge an Glucose, die der Körper resorbiert, beeinflussen. Erfindungsgemäß lässt sich, falls erwünscht, auch eine fast komplette Eliminierung der Glucose bewerkstelligen.Also with sucrose can be achieve a glucose reduction with this combination agent. The while the digestion of the fructose released from the sucrose is how as described above, converted from 5-D-fructose dehydrogenase into 5-keto-D-fructose. The glucose isomerase will then try the resulting Imbalance by converting glucose to fructose. This transformation process will continue until there is no more glucose in the chyme. It is possible that until then part of the for The organism has been readily absorbed by readily available glucose is. However, the amount of total sugars Meal absorbed glucose with the aid of the present invention be significantly reduced. Depending on how high the enzyme activity per dose unit and how high the glucose content of each meal is the amount of glucose that the body absorbed, influence. According to the invention, if desired, also accomplish an almost complete elimination of glucose.
Gegenstand der Erfindung ist deshalb ein Mittel zur Anwendung bei Diabetes, das als Wirkstoffe Glucose-Isomerase und 5-D-Fructose-Dehydrogenase enthält.object the invention is therefore a means for use in diabetes, as active ingredients glucose isomerase and 5-D-fructose dehydrogenase contains.
Die erfindungsgemäße Enzymkombination hat außerdem auch den bei Diabetes erwünschten Effekt der Reduzierung der Kalorienzufuhr, da die Enymkombination, wie oben beschrieben, in der Nahrung enthaltene Kohlenhydrate in unverdauliche 5-Keto-D-Fructose umwandelt. Insbesondere beim Diabetes Typ II ist dies erwünscht, da die Betroffenen häufig an Übergewicht, Bluthochdruck und Fettstoffwechselstörungen leiden.The has enzyme combination according to the invention Furthermore also the effect desired in diabetes the reduction of calorie intake, since the Enymkombination how Carbohydrates contained in the diet described above in indigestible 5-keto-D-fructose transforms. Especially in type II diabetes, this is desirable since those affected frequently overweight, High blood pressure and lipid metabolism disorders suffer.
Die Erfindung beruht somit darauf, dass die in den verzehrten Kohlenhydraten, wie z.B. Saccharose, enthaltene oder aus diesen im Darm freigesetzte Glucose durch die gleichzeitig oder zumindest zeitnah eingenommene Mischung der Wirkstoffe Glucose-Isomerase und 5-D-Fructose-Dehydrogenase durch Umwandlung der Glucose in Fructose und deren anschließende Dehydrierung zu 5-Keto-D-Fructose für die unerwünschte Resorption aus dem Darm in den Blutkreislauf nicht mehr zur Verfügung steht. Die Enzyme werden Glucose in Fructose und diese in die 5-Keto-D-Fructose überführen, bis keine Glucose mehr vorhanden ist. Dabei kann die Dosierung der zugesetzten Enzyme so gewählt werden, dass auch bei Zufuhr größerer Mengen an Glucose die Reaktion schnell genug ablaufen kann.The invention is therefore based on the fact that the glucose contained in the consumed carbohydrates, such as sucrose, or released from these in the intestine by the simultaneous or at least timely taken mixture of the active ingredients glucose isomerase and 5-D-fructose dehydrogenase by conversion of glucose in fructose and its subsequent dehydration to 5-keto-D-fructose for the unwanted absorption from the intestine in the bloodstream is no longer available. The enzymes will turn glucose into fructose and convert it into 5-keto-D-fructose until there is no glucose left. The dosage of the added enzymes can be chosen so that even when larger amounts of glucose, the reaction can proceed quickly enough.
Das erfindungsgemäße Mittel wird in der Regel peroral vor den Mahlzeiten, zu den Mahlzeiten oder unmittelbar danach eingenommen, damit es im Nahrungsbrei seine Wirkung auf Glucose entfalten kann. Das erfindungsgemäße Mittel kann einem Nahrungsmittel auch vor dem Verzehr zugesetzt werden. Es kann auch in immobilisierter Form verwendet werden. Erfindungsgegenstand sind auch Mittel, die neben anderen Wirkstoffen zusätzlich noch eine Kombination der Wirkstoffe Glucose-Isomerase und S-D-Fructose-Dehydrogenase enthalten Das erfindungsgemäße Mittel wird z.B. in Form von Kapseln angewendet, die außer dem Wirkstoff auch noch andere bekannte und übliche Hilfsstoffe enthal ten wie zum Beispiel Dicalciumphosphat, Maltodextrin, mikrokristalline Cellulose und/oder Laktose.The inventive agent is usually taken orally before meals, at mealtimes or taken immediately after, so that it in the porridge its effect can develop on glucose. The agent of the invention may be a food can also be added before consumption. It can also be immobilized Form to be used. Subject of the invention are also means that in addition other active ingredients in addition nor a combination of the active ingredients glucose isomerase and S-D-fructose dehydrogenase contain the agent of the invention is e.g. in the form of capsules, which in addition to the active ingredient also other known and usual Excipients contain such as dicalcium phosphate, maltodextrin, microcrystalline cellulose and / or lactose.
Die Aktivität der Glucose-Isomerase wird erfindungsgemäß in Einheiten definiert, wobei eine Einheit diejenige Menge Glucose-Isomerase ist, die bei einem pH-Wert von 7,5 und einer Temperatur von 37°C aus einer anfänglich 10 gewichtsprozentigen Lösung (d.h. 10 g Fructose + 90 g Wasser) in 5 Minuten 1 g Fructose in Glucose umwandelt.The activity the glucose isomerase is defined according to the invention in units, wherein a unit is that amount of glucose isomerase that is at a pH of 7.5 and a temperature of 37 ° C from an initial 10 percent by weight solution (i.e. 10 g fructose + 90 g water) in 1 minute 1 g fructose Converts glucose.
Bei einer nach dieser Definition bestimmten Enzymaktivität sollte das erfindungsgemäße Mittel Glucose-Isomerase in einer Menge bzw. Aktivität von 0,01 bis 100.000 GIU (=Glucose-Isomerase Units), vorzugsweise 0,05 bis 10.000 GIU und besonders bevorzugt 0,1 bis 1.000 GIU je Dosiseinheit enthalten.at an enzyme activity determined according to this definition should the agent according to the invention glucose isomerase in a crowd or activity from 0.01 to 100,000 GIU (= glucose isomerase units), preferably 0.05 to 10,000 GIU, and more preferably 0.1 to 1000 GIU each Dose unit included.
Das in dem erfindungsgemäßen Mittel enthaltene Enzym 5-D-Fructose-Dehydrogenase sollte in einer Menge bzw. Aktivität von 10 bis 5 Mio. Einheiten, vorzugsweise 25 bis 2,5 Mio. Einheiten und besonders bevorzugt 50 bis 1 Mio. Einheiten je Dosiseinheit vorliegen. Eine Einheit dieses Enzyms ist als diejenige Menge definiert, die bei einem pH-Wert von 4,5 und 37°C pro Minute 1 Mikromol D-Fructose in 5-Keto-D-Fructose umwandelt.The in the agent according to the invention contained enzyme 5-D-fructose dehydrogenase should be in an amount or activity of 10 to 5 million units, preferably 25 to 2.5 million units and more preferably 50 up to 1 million units per dose unit. One unit of this Enzyme is defined as the amount at a pH from 4.5 to 37 ° C 1 micromole of D-fructose per minute to 5-keto-D-fructose.
Besonders vorteilhaft ist es, wenn den erfindungsgemäßen Mitteln neben Glucose-Isomerase und 5-D-Fructose-Dehydrogenase außerdem noch Folsäure, und zwar in einer Menge von 1 bis 100 mg, vorzugsweise 2 bis 50 mg und besonders bevorzugt 3 bis 10 mg je Dosiseinheit zugesetzt wird, da Folsäure die Resorption von Fructose aus dem Darm beschleunigt.Especially It is advantageous if the agents according to the invention in addition to glucose isomerase and 5-D-fructose dehydrogenase as well still folic acid, in an amount of 1 to 100 mg, preferably 2 to 50 mg and more preferably added 3 to 10 mg per unit dose is because folic acid accelerates the absorption of fructose from the intestine.
Die große Bandbreite der vorstehend genannten Dosierungen erklärt sich dadurch, dass das erfindungsgemäße Mittel bei ganz verschiedenen Arten von Diabetes in ihren verschiedensten Schweregraden eingesetzt wird. Außerdem ergeben sich die unterschiedlichen Dosierungen auch dadurch, dass in Abhängigkeit von der jeweiligen Nahrung stark variierende Mengen von Glucose zugeführt werden.The size Bandwidth of the above doses is explained in that the agent according to the invention in very different types of diabetes in their most diverse Severity is used. In addition, the different arise Dosages also in that, depending on the particular Food strongly varying amounts of glucose are supplied.
Ein erfindungsgemäßes Mittel in Kapseln (z.B. der Größe 3) könnte z.B. pro Kapsel 55 mg S-D-Fructose-Dehydrogenase (Aktivität der 5-D-Fructose-Dehydrogenase 1000 Einheiten/mg), 50 mg Glucose-Isomerase (Aktivität der Glucose-Isomerase 1 GIU/mg) und 55 mg Dicalciumphosphat enthaltenOne Composition according to the invention in capsules (e.g., size 3), e.g. 55 mg per capsule of S-D-fructose dehydrogenase (activity of 5-D-fructose dehydrogenase 1000 Units / mg), 50 mg glucose isomerase (activity of glucose isomerase 1 GIU / mg) and 55 mg dicalcium phosphate
Ein weiteres Zusammensetzungsbeispiel für die Herstellung von Kapseln (z.B. der Größe 00) könnte pro Kapsel 165 mg S-D-Fructose-Dehydrogenase (Aktivität der 5-D-Fructose-Dehydrogenase 1000 Einheiten/mg), 150 mg Glucose-Isomerase (Aktivität der Glucose-Isomerase 1 GIU/mg) und 155 mg Dicalciumphosphat enthalten.One Another composition example for the production of capsules (e.g., size 00) could be per Capsule 165 mg S-D-fructose dehydrogenase (activity of 5-D-fructose dehydrogenase 1000 Units / mg), glucose glucose isomerase 150 mg (activity of glucose isomerase 1 GIU / mg) and 155 mg dicalcium phosphate.
Mit dem erfindungsgemäßen Mittel können durch Diabetes unterschiedlichen Schweregrades hervorgerufene Beschwerden und gesundheitliche Beeinträchtigungen erheblich gemindert oder beseitigt werden.With the agent of the invention can through Diabetes of varying severity caused discomfort and health problems be significantly reduced or eliminated.
Claims (7)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005056103A DE102005056103A1 (en) | 2005-11-23 | 2005-11-23 | Agent, useful to treat diabetes, comprises 5-D-fructose-dehydrogenase and glucose isomerase |
| EP06818756.6A EP1951293B1 (en) | 2005-11-23 | 2006-11-23 | Agent for use in the case of disorders of blood sugar metabolism, including diabetes |
| PCT/EP2006/011232 WO2007059956A1 (en) | 2005-11-23 | 2006-11-23 | Agent for use in the case of disorders of blood sugar metabolism, including diabetes |
| US12/094,684 US20090214620A1 (en) | 2005-11-23 | 2006-11-23 | Agent for use in the case of disorders of blood sugar metabolism, including diabetes |
| IL191365A IL191365A0 (en) | 2005-11-23 | 2008-05-12 | Agent for use in the case of disorders of blood sugar metabolism, including diabetes |
| US14/140,600 US9415093B2 (en) | 2005-11-23 | 2013-12-26 | Agent for use in the case of disorders of blood sugar metabolism, including diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005056103A DE102005056103A1 (en) | 2005-11-23 | 2005-11-23 | Agent, useful to treat diabetes, comprises 5-D-fructose-dehydrogenase and glucose isomerase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE102005056103A1 true DE102005056103A1 (en) | 2007-05-24 |
Family
ID=37989598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE102005056103A Withdrawn DE102005056103A1 (en) | 2005-11-23 | 2005-11-23 | Agent, useful to treat diabetes, comprises 5-D-fructose-dehydrogenase and glucose isomerase |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE102005056103A1 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4396602A (en) * | 1981-09-22 | 1983-08-02 | Asahi Kasei Kogyo Kabushiki Kaisha | Blood glucose level lowering agents |
| WO1999057986A1 (en) * | 1998-05-13 | 1999-11-18 | Novo Nordisk Biotech, Inc. | Methods for using dehydrogenases in baking |
| US6395299B1 (en) * | 1999-02-12 | 2002-05-28 | Biostream, Inc. | Matrices for drug delivery and methods for making and using the same |
| WO2003051391A1 (en) * | 2001-12-17 | 2003-06-26 | N.V. Nutricia | Method of treating obesity, overweight, diabetes, or fluctuations in blood insuline or glucose levels |
-
2005
- 2005-11-23 DE DE102005056103A patent/DE102005056103A1/en not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4396602A (en) * | 1981-09-22 | 1983-08-02 | Asahi Kasei Kogyo Kabushiki Kaisha | Blood glucose level lowering agents |
| WO1999057986A1 (en) * | 1998-05-13 | 1999-11-18 | Novo Nordisk Biotech, Inc. | Methods for using dehydrogenases in baking |
| US6395299B1 (en) * | 1999-02-12 | 2002-05-28 | Biostream, Inc. | Matrices for drug delivery and methods for making and using the same |
| WO2003051391A1 (en) * | 2001-12-17 | 2003-06-26 | N.V. Nutricia | Method of treating obesity, overweight, diabetes, or fluctuations in blood insuline or glucose levels |
Non-Patent Citations (1)
| Title |
|---|
| Chen, W.P. und Anderson, A.W., In: Appl. Environ. Microbiol., 1979, Vol. 38, S. 1111-1119 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60215156T2 (en) | ACID-REDUCED VISCOSES BALANCE SYSTEM AND ITS USE | |
| DE60220182T2 (en) | ALCOHOL-FREE BEVERAGE SET | |
| DE69815323T2 (en) | THERAPEUTIC FOOD FOR DIABETICS | |
| EP2124972B1 (en) | Use of a composition made of mineral nutrients and optionally acetogenic and/or butyrogenic bacteria in order to avoid or reduce the formation of gas in the large intestine of a mammal and the resulting abdominal problems | |
| DE60207877T2 (en) | Composition containing procyanidins for reducing appetite in mammals | |
| DE60309169T2 (en) | USE OF THE PULLULAN AS SLOWLY DIGESTIVE CARBOHYDRATE | |
| WO2013078658A1 (en) | Morus berries and avoiding glucose peaks | |
| DE102007008664B4 (en) | Means for use in fructose intolerance | |
| DE60002484T2 (en) | COMPOSITION THAT CONTAINS AN ALPHA AMYLASE INHIBITOR AND AT LEAST ONE PHYSIOLOGICALLY ACCEPTABLE COMPONENT THAT CAN REDUCE THE INTESTINAL ABSORPTION OF "FAST SUGARS" | |
| DE102010038644A1 (en) | Composition, useful as supplementary food composition e.g. to reduce cholesterol formation and triglyceride absorption, comprises at least three soluble dietary fibers, preferably neutral dietary fibers and a cation | |
| WO2017032665A1 (en) | Mineral compositions for stimulating the carbohydrate metabolism | |
| DE102006013624B4 (en) | Means for use in fructose intolerance | |
| DE10008279A1 (en) | Synergistic medicinal or health-promoting food additive composition, comprising lactose, inulin and/or oligofructose, calcium salt and Bifidus bacteria, having e.g. immunostimulant and digestion improving action | |
| DE102005056103A1 (en) | Agent, useful to treat diabetes, comprises 5-D-fructose-dehydrogenase and glucose isomerase | |
| DE69232126T3 (en) | Ingestible preparations containing water-soluble, highly viscous cellulose ethers | |
| CN106262569A (en) | A kind of nutraceutical of three-hypers patient | |
| US20050003027A1 (en) | Chemical composition and method to bind fat, enhance metabolization, and aid digestion | |
| DE69936190T2 (en) | USE OF ITACONIC ACID FOR REGULATING GLYCOLYTIC METABOLISM | |
| DE102005061329A1 (en) | Use of glucose isomerase in combination with 5-D-fructose dehydrogenase and an enzyme, e.g. invertase, for producing a pharmaceutical composition for preventing, treating, or diagnosing diabetes | |
| JP2010059105A (en) | Preventing or treating agent for inflammatory bowel disease | |
| AT412381B (en) | Combined nutritional supplement, useful particularly for increasing sporting performance, contains mixture of inorganic salts, amino acids, vitamins and carbohydrates, also creatine, inositol and tocopherol | |
| DE102006014420A1 (en) | New 5-D-fructose dehydrogenase in combination with an enzyme, e.g. glucose isomerase, useful for preventing or treating adiposity | |
| DE10352822A1 (en) | Use of an additionally fermented cereal sludge for the prevention and / or treatment of elevated blood sugar levels | |
| DE102006001017A1 (en) | Use of glucose isomerase in combination with 5-D-fructose dehydrogenase and an enzyme, e.g. invertase, for producing a pharmaceutical composition for preventing, treating, or diagnosing diabetes | |
| WO2005004990A1 (en) | Use of whey permeate for the treatment of metabolic syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| 8139 | Disposal/non-payment of the annual fee |